The innovative company Singular Medical specializes in the treatment of arrhythmia
Singular Medical (Chinese: 无双医疗) recently announced that it had raised over CNY 100 million in Series B+, which was led by Lotus Lake Capital (Chinese: 荷塘创投), HWealth Capital (Chinese: 康裕资本) and its existing investor QiMing Venture Partners (Chinese: 启明创投). DAS Capital (Chinese: 点石资本) served as the exclusive financial adviser. Proceeds raised in this funding will be used in the promotion of clinical trial, product pipelines expansion, and team building.
Founded in 2017, Singular Medical is a leading medical equipment company specializing in R&D and industrialization of cardiac rhythm management (CRM) products with independent intellectual property rights. It is based in the Medpark of National Hi-tech District of Suzhou and operates critical process development and pilot manufacturing center in Minnesota, US and R&D centers in California, US.
Singular Medical starts with the highest technology, ICD, in heart rhythm management area and builds the technology platform for the treatment of heart rhythm and heart failure. It provides a full spectrum of heart health products and services for doctors and patients, from prevention and diagnosis to treatment and monitoring. Singular Medical's product lines include ICD system, new pacemaker, implantable and wearable cardiac monitoring system and arrhythmia digitalization cloud platform. To date, Singular Medical has obtained 120 China patents and 5 US patents.
Singular Medical's competitors include Qinming (Chinese: 乐普医电), MicroPort (Chinese: 微创医疗) and Med-zenith (Chinese: 迈迪顶峰).